Product DevelopmentThe ANDA could lead to approval of the only preservative-free form of ketamine, making it a unique product in the market.
Regulatory ProgressFDA waived the $4.3M NDA Submission fee for NRX-101, reducing financial burden on the company.
Strategic PartnershipsManagement has indicated significant interactions with developers of TMS equipment, suggesting strong strategic partnerships to offer comprehensive treatment solutions.